Two new drugs were resubmitted for FDA approval last week.
1. Rhopressa – dosed once a day to reduce IOP. The drop works via three different mechanisms:
a. It increases fluid outflow through the trabecular meshwork by inhibiting Rho Kinase (ROCK)
b. Reduces fluid production in the eye by inhibiting norepinephrine transporter (NET)
c. Lowers episcleral venous pressure.
2. Latanoprostene bunod (aka VESNEO) is thought to increase aqueous humor outflow by acting on both the uveoscleral pathway (unique – no other drop works here) and trabecular meshwork and Schlemm’s canal (conventional pathway).
However, your office won’t see any new drug reps for this yet. New drug applications with the FDA typically take around one year to complete.